KKR's Third Quarter Results Sees AUM Grow, Helped By Asia Fundraising
KKR announced its third quarter results today, showing overall AUM of $233.8bn, up from $221.8bn at the end of the second quarter of the year. Fee-paying AUM stood at $177.3 billion as of September 30, 2020 compared to $160.3 billion as of June 30. KKR says that the increase in fee-paying AUM is primarily attributable to new capital raised in the firm's Asia and core private equity strategies, real asset strategies, and leveraged and private credit strategies. KKR’s Asian Fund IV, which launched in July this year, has raised just over $13bn, all of which was yet to be called at the end of the quarter. The firm’s Asian Fund III, which still had $3.7bn to call at the end of September, is producing a net IRR of 24%, according to the firm’s investor update presentation.
Private equity still dominates the firm's book. 71% of the firms holdings are categorised as private equity investments, with real estate the next highest at 8%. Fiserv remains the firm's highest exposure, with a fair value of $1.47bn, 10.5% of the firm's total investments. Other 'significant investments' identified by KRR include USI, Inc; BridgeBio Pharma, Inc; PetVet Care Centers, LLC; and Heartland Dental, LLC.
© The Sortino Group Ltd
All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency or other Reprographic Rights Organisation, without the written permission of the publisher. For more information about reprints from AlphaWeek, click here.